Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Phylos Bioscience Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 3 distinct examiners, indicating a lack of examiner concentration for the current workload. The presence of 2 distinct art units suggests that the company's intellectual property spans multiple specialized examination groups within the biotechnology sector. This diversity in art units often requires distinct technical arguments tailored to different supervisory standards.
KEITH RICHARD WILLIAMS is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Because the busiest examiner is responsible for 1 pending office action, the workload is shared among the other distinct examiners. This distribution requires the applicant to adapt to the specific preferences and historical tendencies of multiple individual examiners simultaneously. Navigating 2 distinct art units further complicates this process by introducing different administrative protocols.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIAMS, KEITH RICHARD | 1 | 50.0% | +0.0% |
| DEVEAU ROSEN, JASON | 1 | 80.1% | +16.5% |
| KRUSE, DAVID H | 1 | 81.3% | +9.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837849 | CANNABINOID MARKERS | DEVEAU ROSEN, JASON | — |
| 18681833 | VARIN GENES | KRUSE, DAVID H | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866040 | AUTOFLOWERING GENES | WILLIAMS, KEITH RICHARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837849 | CANNABINOID MARKERS | DEVEAU ROSEN, JASON | — |
| Art Unit | Apps |
|---|---|
| 1663 | 2 |
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866040 | AUTOFLOWERING GENES | WILLIAMS, KEITH RICHARD | 1663 | §101§102 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18837849 | CANNABINOID MARKERS | DEVEAU ROSEN, JASON | 1662 | §102§112DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18681833 | VARIN GENES | KRUSE, DAVID H | 1663 | §102§112DP | Non-Final OA | — | Pending | Feb 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial